FLCCC Observational Cancer Study

Turbo cancers are a rapidly escalating threat in the wake of the COVID pandemic, forcing doctors to push the boundaries of traditional oncology treatment. In this presentation, Dr. Kathleen Ruddy, Dr. Paul Marik, and Dr. Nathan Goodyear introduced groundbreaking adjunctive treatment strategies that are reshaping cancer care.

Dr. Paul Marik counters the monied special interests of medical journals with evidence-based, conflict-of-interest-free research.

Paul Mann had advanced cancer, which his oncologist said was terminal. He had over a dozen radiation treatments and six rounds of chemotherapy and was put in hospice care twice. Then he met Dr. Kathleen Ruddy. Watch his hopeful MyStory filmed at the FLCCC Conference in Phoenix.

Special guest, professor and oncologist Dr. Angus Dalgleish, joined Dr. Pierre Kory and Dr. Paul Marik for an important discussion on cancer and its connection to COVID shots and boosters.

Dr. Paul Marik and Executive Director Kelly Bumann recap FLCCC's 3rd educational conference and discuss the recently launched FLCCC Observational Cancer Study.

The FLCCC Alliance is proud to announce it has partnered with renowned breast cancer physician and researcher Kathleen Ruddy, MD, to conduct an observational study in collaboration with five U.S. clinics to track patient responses to various adjunct cancer therapies using repurposed drugs.